The device is designed for use in any chamber of the heart during cardiac ablation. Physicians use mapping catheters to identify areas of cardiac tissue that are responsible for sending erratic electrical signals that cause arrhythmias.
Abbott touted its device as having a first-of-its-kind grid configuration of electrodes that improves data collection.
Linear or circular mapping catheters sometimes experience signal disruptions when the orientation of the catheter changes, Abbott explained. But its Advisor HD Grid device is designed to avoid signal loss by collecting data horizontally and vertically along a grid that’s configured with 16 sensors.
The catheter captures data through both impedance and magnetic collection. Using that data, the Advisor HD Grid catheter creates detailed and anatomically-accurate 3D models of the heart.
Abbott’s device, combined with the EnSite Precision cardiac mapping system, allows doctors to create a map detailing the differences between healthy tissue and the tissue causing a patient’s arrhythmias.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.